Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma

•Phase 1 trial of concomitant ralimetinib with radiotherapy (and TMZ) in glioblastoma patients.•First worldwide phase 1 trial to evaluate the combination of a p38-MAPK inhibitor (ralimetinib) with radiotherapy.•The recommended dose of ralimetinib was 100 mg/12 h with chemoradiotherapy.•At recommende...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Radiotherapy and oncology 2021-01, Vol.154 (227-234), p.227-234
Hauptverfasser:	Biau, J., Thivat, E., Chautard, E., Stefan, D., Boone, M., Chauffert, B., Bourgne, C., Richard, D., Molnar, I., Levesque, S., Bellini, R., Kwiatkowski, F., Karayan-Tapon, L., Verrelle, P., Godfraind, C., Durando, X.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Alkylating - therapeutic use Brain Neoplasms - drug therapy Cancer Chemoradiotherapy Dacarbazine - therapeutic use Glioblastoma Glioblastoma - drug therapy Hematology Human health and pathology Humans Imidazoles Leukocytes, Mononuclear Life Sciences Neurobiology Neurons and Cognition Pharmaceutical sciences Pharmacology Phase I clinical trial Pyridines Radiotherapy Ralimetinib Temozolomide Temozolomide - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!